{"disease":{"id":"hematologic-malignancies","name":"hematologic malignancies"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02457962","title":"Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking Study","phase":"","overall_status":"RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04142372","title":"Tissue Microarray of Hematological Malignancies","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Tampere University Hospital","has_results":false},{"nct_id":"NCT03486873","title":"Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":3500,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT04733729","title":"Covid-19 in Hematological Malignancies","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Sorveglianza Epidemiologica Infezioni Fungine Emopatie Maligne","has_results":false},{"nct_id":"NCT01345019","title":"Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1718,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT06607289","title":"National Longitudinal Cohort of Hematological Diseases (NICHE) - CART","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT02473757","title":"Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06550102","title":"Drug Response Profiling (DRP) Registry Zurich for Hematological Malignancies","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"University Children's Hospital, Zurich","has_results":false},{"nct_id":"NCT01375842","title":"A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":661,"lead_sponsor_name":"Genentech, Inc.","has_results":false},{"nct_id":"NCT06674330","title":"Using a Population Pharmacokinetic Model to Estimate the Dosage of Teicoplanin in Patients With Hematologic Malignancy or Critical Illness","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":600,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT04634552","title":"A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":510,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT05103995","title":"Impact of Donor-recipient ABO Matching on Haploidentical Stem Cell Transplantation","phase":"","overall_status":"COMPLETED","enrollment_count":510,"lead_sponsor_name":"First Affiliated Hospital of Zhejiang University","has_results":false},{"nct_id":"NCT06296368","title":"DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics","phase":"NA","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"UNC Lineberger Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT02315599","title":"Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":500,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04389541","title":"Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology","phase":"","overall_status":"COMPLETED","enrollment_count":499,"lead_sponsor_name":"iOMEDICO AG","has_results":false},{"nct_id":"NCT04728893","title":"Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":490,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT02964325","title":"Efficacy of Mirasol-treated Apheresis Platelets in Patients With Hypoproliferative Thrombocytopenia","phase":"NA","overall_status":"TERMINATED","enrollment_count":422,"lead_sponsor_name":"Terumo BCTbio","has_results":true},{"nct_id":"NCT07220616","title":"A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":420,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT05290545","title":"Haplo-PBSC+Cord vs Haplo-PBSC+BM for Hematological Malignancies Undergoing Allo-HSCT","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":314,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT03145181","title":"Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":302,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT04878822","title":"Immunogenicity of Covid-19 Vaccination for Patients With Hematological Malignancies","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Ospedale di Circolo - Fondazione Macchi","has_results":false},{"nct_id":"NCT06150469","title":"Efficacy of Inhaled Aromatherapy on Nausea and Vomiting in Hematological Malignancies","phase":"NA","overall_status":"RECRUITING","enrollment_count":286,"lead_sponsor_name":"University Hospital, Limoges","has_results":false},{"nct_id":"NCT01607892","title":"Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":286,"lead_sponsor_name":"Karyopharm Therapeutics Inc","has_results":true},{"nct_id":"NCT07195916","title":"A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":280,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT03399799","title":"Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":279,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT05470491","title":"Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":265,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03248479","title":"Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":258,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT04352556","title":"COVID19-hematological Malignancies: the Italian Hematology Alliance","phase":"","overall_status":"UNKNOWN","enrollment_count":250,"lead_sponsor_name":"Ospedale di Circolo - Fondazione Macchi","has_results":false},{"nct_id":"NCT03733340","title":"Antibacterial Prophylaxis vs no Prophylaxis for Hematological Malignancies Patients Before Allo-HSCT","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":250,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT02663518","title":"A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":249,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT06378138","title":"ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":226,"lead_sponsor_name":"Beijing InnoCare Pharma Tech Co., Ltd.","has_results":false},{"nct_id":"NCT04557098","title":"A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":194,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT05005442","title":"A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":192,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT05728658","title":"The Study of ICP-248 in Patients With Mature B-cell Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":191,"lead_sponsor_name":"Beijing InnoCare Pharma Tech Co., Ltd.","has_results":false},{"nct_id":"NCT07186192","title":"Digital Health Intervention for Self-Management and Telemonitoring in Chimeric Antigen Receptor (CAR-T) Therapy","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":190,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT01010217","title":"Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":176,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT05028478","title":"A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":164,"lead_sponsor_name":"Curon Biopharmaceutical (Australia) Co Pty Ltd","has_results":false},{"nct_id":"NCT04588922","title":"Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":160,"lead_sponsor_name":"Sellas Life Sciences Group","has_results":false},{"nct_id":"NCT07162038","title":"Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":155,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03082209","title":"A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":153,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT05952804","title":"IVIG for Infection Prevention After CAR-T-Cell Therapy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT05690581","title":"Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":146,"lead_sponsor_name":"Beijing InnoCare Pharma Tech Co., Ltd.","has_results":false},{"nct_id":"NCT04657965","title":"LMP1 CAR-T for Patients With LMP1 Positive Infectious Diseases and Hematological Malignancies","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":144,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT05724121","title":"Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax","phase":"","overall_status":"RECRUITING","enrollment_count":135,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT06387082","title":"A Clinical Study of HMPL-506 in Patients With Hematological Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Hutchmed","has_results":false},{"nct_id":"NCT02730299","title":"Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":125,"lead_sponsor_name":"Gamida Cell ltd","has_results":true},{"nct_id":"NCT05306509","title":"Nurse-initiated Conversations for Early Integration of Palliative Care in Pediatric Oncology","phase":"NA","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Children's Hospital of Fudan University","has_results":false},{"nct_id":"NCT06834412","title":"A Study Evaluating the Value of 68Ga-Pentixafor PET Imaging in the Staging of Hematological Tumor, and Comparing It with 18F-FDG PET/CT Imaging","phase":"NA","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Xijing Hospital","has_results":false},{"nct_id":"NCT02223598","title":"A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":120,"lead_sponsor_name":"Cleave Biosciences, Inc.","has_results":false},{"nct_id":"NCT05020639","title":"A Study of TQB3820 in Patients With Hematological Malignancies","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":116,"lead_sponsor_name":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}